Clinical trials
GLP-1 clinical trials
Below are recruiting glp-1 clinical trials, each written for real people, not researchers. We’re tracking 94 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07210684Recruiting
Dihydroberberine for blood sugar, appetite, and mood in prediabetes
This study tests a supplement called dihydroberberine (DHB) to see if it helps improve blood sugar control, appetite, and mood in adults with prediabetes. You will wear a small sensor to track your blood sugar and use a phone app to record what you eat.
Addison, IllinoisAges 35–65 - NCT07117240Enrolling by invitationPhase 4
GLP-1 drugs for steroid-induced diabetes
This trial tests whether a GLP-1 receptor agonist (a type of diabetes medication) can safely and effectively treat high blood sugar caused by long-term steroid use. It may help people with type 2 diabetes or steroid-induced diabetes who take oral steroids for conditions like asthma, arthritis, or kidney disease.
Warsaw, WarsawAges 18 years+ - NCT07107334RecruitingPhase 2
GLP-1 drug plus hormone IUD for early endometrial cancer in obesity
This trial tests if adding a GLP-1 weight-loss drug to a hormone-releasing IUD can help treat very early endometrial cancer or a precancerous condition in women with obesity. The goal is to see if this combination is effective without surgery.
Gainesville, FloridaAges 18 years+ - NCT07104539Recruiting
Strength training for people starting GLP-1 weight loss meds
This study looks at how strength training affects your muscles if you're just starting a GLP-1 medicine for weight loss (like Wegovy or Zepbound). It's designed to help understand if exercise can help preserve muscle while you lose weight.
Blacksburg, VirginiaAges 50 years+ - NCT07091500Recruiting
Exercise and a weight-loss drug for people with obesity
This trial tests whether combining a GLP-1 medication (a type of diabetes drug that also helps with weight loss) with an exercise program can improve physical function in people with obesity. If you are obese and have trouble with daily activities, this study may help you become more mobile and healthier.
St Louis, MissouriAges 50–75 - NCT07057310Enrolling by invitationPhase 4
Weight Loss Drug for Postmenopausal Women With Obesity
This study tests a GLP-1 agonist medication (like Ozempic) to help postmenopausal women lose weight and improve physical and blood vessel health. It focuses on women aged 46–60 with obesity.
Jacksonville, FloridaAges 46–60 - NCT06967558RecruitingPhase 2
GLP-1 hormone role in prediabetes
This study looks at how a hormone called GLP-1, made in the pancreas, affects blood sugar levels in people with borderline high blood sugar (prediabetes). It may help find new ways to prevent diabetes.
Rochester, MinnesotaAges 25–70 - NCT06891287RecruitingPhase 1
Testing an oral GLP-1/2 capsule in healthy volunteers
This study tests a new oral capsule that delivers a medicine called PG-102, which is a dual GLP-1/2 agonist (similar to drugs used for diabetes and weight loss). It is for healthy volunteers to see how the body handles the medicine. The study has two parts: one for people with a lower BMI and one for people with a higher BMI (over 30).
Melbourne, VictoriaAges 18–65 - NCT06889454Recruiting
Heart and blood vessel changes in women with PCOS after treatment
This trial looks at how the heart's blood vessels and certain markers change in women with PCOS when they drink a sugary solution (OGTT). It checks these markers before treatment starts and again 6 and 12 months after, to help understand cardiovascular risk in PCOS.
ChaïdáriAges 18–45 - NCT06839248Recruiting
Fasting before procedures with GLP-1 meds
This study looks at whether people taking weekly GLP-1 medications (like Ozempic or Wegovy) should follow standard fasting rules or a 24-hour clear liquid diet before a procedure. The goal is to find the safest way to prepare.
Melbourne, VictoriaAges 18 years+ - NCT06814080Recruiting
Stomach Content Study for GLP-1 Users Before Surgery
This study looks at whether a common diabetes medication (GLP-1) affects how much food stays in your stomach before surgery. It aims to make anesthesia safer by understanding stomach content.
Little Rock, ArkansasAges 18 years+ - NCT00992901RecruitingEarly Phase 1
Testing hormones and nerve signals after gastric bypass
This early-phase study looks at how the body’s hormone signals and nerve control affect insulin release after gastric bypass surgery. It may help researchers understand what drives low blood sugar and how to better monitor or treat it.
San Antonio, TexasAges 18–65 - NCT06411210RecruitingPhase 2
Weight loss medication for young adults with type 1 diabetes
This study tests whether a GLP-1 medication (a type of drug that helps with weight loss) can safely and effectively help young adults with type 1 diabetes who also have obesity. It aims to see if adding this treatment to insulin can improve weight and blood sugar control.
New Haven, ConnecticutAges 18–30 - NCT06256419Recruiting
Gene testing and exenatide response in Chinese type 2 diabetes patients
This study looks at how certain genes affect the risk of type 2 diabetes and how well the drug exenatide (a GLP-1 receptor agonist) works in Chinese patients. It aims to see if your genetic makeup can predict how you will respond to treatment.
Xuzhou, ChinaAges 25–70 - NCT06324461RecruitingPhase 4
GLP-1 drug to protect heart after non-emergency surgery
This study tests whether a GLP-1 receptor agonist (a medication used for diabetes and weight loss) can reduce heart damage during or after planned non-cardiac surgery. It may help patients with heart risk undergoing intermediate to high-risk procedures.
Hong Kong, Hong Kong SARAges 18 years+ - NCT05390892RecruitingPhase 4
Preventing kidney and heart damage in type 2 diabetes
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
Huntsville, AlabamaAges 40–80 - NCT05119179RecruitingPhase 4
Testing how genetics affect GLP-1 response in prediabetes
This study looks at how your genes may change how well a GLP-1–type medicine works to improve prediabetes. It focuses on adults at higher risk of developing diabetes, especially people of Mexican-American background.
Brownsville, TexasAges 18 years+ - NCT04731272RecruitingPhase 2
Weekly GLP-1 medicine for blood sugar issues in adults with CF
This Phase 2 trial tests a weekly GLP-1 medicine (dulaglutide) to improve blood sugar control in adults with cystic fibrosis (CF) who have trouble managing glucose. It may help people with CF-related prediabetes or diabetes by improving how their body handles sugar.
Aurora, ColoradoAges 18 years+ - NCT04575844RecruitingPhase 4
Exercise and GLP-1 to improve insulin and muscle blood flow
This study looks at whether doing exercise and a GLP-1 medicine (liraglutide or similar) can improve how your body uses insulin and how blood flows to your muscles. It is aimed at adults with metabolic syndrome who do not already have diabetes.
Charlottesville, VirginiaAges 21–60 - NCT01851694Recruiting
Study incretin hormone response in adults with cystic fibrosis
This study tests how the body’s “incretin” hormones affect insulin (sugar control) in adults with cystic fibrosis and certain blood sugar patterns. It may help explain what drives diabetes risk in cystic fibrosis and how the body responds to these hormone signals.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03878706Recruiting
Testing diabetes medicines on heart risk and heart failure
This trial studies how diabetes medicines (GLP-1 and SGLT2, alone or together) affect the heart in people with type 2 diabetes who are at higher cardiovascular risk and have heart failure with preserved pumping function. It may help find safer or more effective ways to reduce heart problems.
Athens, AtticaAges 45–80 - NCT07575399RecruitingPhase 3
Switching to a New Weight-Loss Medication From Current GLP-1
This trial tests whether switching from your current GLP-1 medication (like Ozempic or Wegovy) to a new drug called maridebart cafraglutide works as well or better for weight management. You must have already lost at least 10% of your body weight on your current GLP-1 and be doing well with it.
Pelham, AlabamaAges 18–99
Hear when a new GLP-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glp-1?
- Yes. Clin2 currently lists 94 recruiting glp-1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glp-1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glp-1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.